Paloma Partners Management CO Supernus Pharmaceuticals, Inc. Transaction History

Paloma Partners Management CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$26.72 - $33.19 $230,647 - $286,496	-8,632 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$24.15 - $31.45 $208,462 - $271,476	8,632 New	8,632 $226,000
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $224,418 - $327,244	-12,679 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$20.2 - $25.05 $46,641 - $57,840	2,309 Added 22.27%	12,679 $264,000
Q2 2020 Aug 14, 2020	BUY	$17.09 - $24.89 $177,223 - $258,109	10,370 New	10,370 $247,000
Q1 2019 May 15, 2019	SELL	$32.77 - $41.99 $236,927 - $303,587	-7,230 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$30.84 - $49.51 $222,973 - $357,957	7,230 New	7,230 $240,000
Q2 2018 Aug 14, 2018	SELL	$44.1 - $59.85 $1.11 Million - $1.51 Million	-25,193 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$37.15 - $46.9 $211,049 - $266,438	5,681 Added 29.12%	25,193 $1.15 Million
Q4 2017 Feb 14, 2018	SELL	$36.4 - $42.6 $696,768 - $815,449	-19,142 Reduced 49.52%	19,512 $778,000
Q3 2017 Nov 14, 2017	BUY	$36.75 - $49.65 $1.42 Million - $1.92 Million	38,654	38,654 $1.55 Million

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

Stay updated on Paloma Partners Management CO with notifications on news.